This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Diabetes-Drug Makers Face FDA Hurdle

The FDA convened an advisory panel last summer that recommended drug companies conduct long-term cardiovascular risk trials for all diabetes drug candidates, regardless of whether there was any prior evidence of a heart safety signal during clinical testing.

The new FDA letters essentially follow up on that recommendation, informing drugmakers that they must collect cardiac safety data for any diabetes drug currently in clinical studies.

The letters do not offer specific instructions on how the data are to be collected. If a company can collect the relevant safety data from existing or ongoing clinical trials, any delay caused by the FDA request may be relatively minor.

However, any company that has to start new studies to collect the heart-safety data could face significant delays and added expense.

Amylin and partner Eli Lilly (LLY) are co-developing Byetta LAR, also known as "exenatide once weekly," a long-acting version of their currently marketed diabetes drug Byetta. A spokesperson for Amylin confirmed the receipt of the FDA letter.

"Amylin and Lilly have discussed our submission plans with the FDA in our pre-NDA [new-drug application] meeting and are confident that we have sufficient clinical data to submit an NDA for exenatide once weekly," she said.

Moreover, she added, "Available clinical trial data for both Byetta and exenatide once weekly do not indicate an increased risk for cardiovascular events."

Novo Nordisk's new diabetes drug liraglutide is currently under FDA review, with an FDA-sponsored advisory committee meeting scheduled for April 2-3, 2009. That meeting is expected to offer clarification as to what the FDA is likely to require of companies with new and pending drug applications.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BMY $66.50 0.80%
AZN $63.74 -0.93%
GSK $41.64 -0.93%
INCY $104.23 3.40%
NVO $54.77 0.15%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs